Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003568 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
A Phase 2 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003568 is a Phase 2 study that has completed, run by University of Illinois at Chicago.
The verdict
NCT00003568, a Phase 2 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy with interleukin-2 in treating patients with metastatic melanoma.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL gp100 antigen
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-11 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003568
The ClinicalTrials.gov registry entry for NCT00003568 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which aldesleukin is the first listed.
NCT00003568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003568 about?
NCT00003568 is a clinical study titled "Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma". RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy with interleukin-2 in treating patients with m...
What is the current status of trial NCT00003568?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-11. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00003568?
The interventions under investigation include: aldesleukin (BIOLOGICAL), incomplete Freund's adjuvant (BIOLOGICAL), gp100 antigen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003568?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.